OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma

ABSTRACT: Abstract

Introduction

Liquid biopsy for the detection and monitoring of brain tumors is of significant clinical interest. The ability to non-invasively profile tumors can avoid a risky biopsy and opens avenues for testing novel therapies by accurately stratifying patients to receive the right therapy. Here, we provide evidence of EV RNA-based diagnosis, patient stratification, and assessment of response to therapy in the setting of a clinical trial evaluating the efficacy of dacomitinib, an EGFR tyrosine kinase inhibitor in patients with recurrent, EGFR amplified GBM(NCT01112527).

Methods

We performed RNASeq on long RNA extracted from the serum samples, pre-treatment and 1-month post-treatment.

Results

Firstly, longRNASeq allowed the detection of thousands of mRN

SUBMITTER: Yekula A 

PROVIDER: S-EPMC8255422 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature